1、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(May1,2025)-Amgen(NASDAQ:AMGN)today announced financial results for the first quarter of 2025.“Demand for our products was strong globally in the first

2、 quarter.Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,”said Robert A.Bradway,chairman and chief executive officer.Key results include:For the first quarter,total revenues increased 9%to$8.1 billion in

3、comparison to the firstquarter of 2024.Product sales grew 11%,primarily driven by 14%volume growth,partially offset by 6%lower net selling price.U.S.sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter,including Repatha(evolocumab),BLINCYTO(blinatumomab)

4、,TEZSPIRE(tezepelumab-ekko),EVENITY(romosozumab-aqqg),TAVNEOS(avacopan),andUPLIZNA(inebilizumab-cdon).Our launch of IMDELLTRA(tarlatamab-dlle)generated$81 million of sales in thequarter and the Phase 3 confirmatory study demonstrated improved overall survivalcompared to chemotherapy.IMDELLTRA launch

5、ed in Japan in April 2025.GAAP earnings per share(EPS)were$3.20 for the first quarter of 2025 compared with aGAAP loss per share of$0.21 for the first quarter of 2024,resulting from an unrealized gainon our BeiGene,Ltd.equity investment during the first quarter of 2025 compared to anunrealized loss

6、during the prior year period,partially offset by an Otezla intangible assetimpairment charge of$800million recorded during the first quarter of 2025.GAAP operating income increased from$1.0 billion to$1.2 billion,and GAAPoperating margin increased 1.1 percentage points to 15.0%.Non-GAAP EPS increase